Please assess the completion status of the following clinical trial:

Trial Title: Mucinex® for Treatment of Filamentary Keratitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with filamentary keratitis~* 18 years and older~Exclusion Criteria:~* Active ocular surface infection of any type~* Recent ocular surgery (\<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones~* Schirmer's test\<3mm~* History of hypersensitivity to Mucinex®~* Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mucinex (Type: OTHER): 600 mg of Mucinex 2 times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).